1-benzyl 4-[4-((E)-1-4-[2-(dimethylamino)ethoxy]phenyl-2-phenyl-1-butenyl)phenyl]tetrahydro-1,4(2H)-pyridinedicarboxylate | 267408-81-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 1-benzyl 4-[4-((E)-1-4-[2-(dimethylamino)ethoxy]phenyl-2-phenyl-1-butenyl)phenyl]tetrahydro-1,4(2H)-pyridinedicarboxylate
• 英文别名: 1-O-benzyl 4-O-[4-[(E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenyl] piperidine-1,4-dicarboxylate
• CAS: 267408-81-1
• 化学式: C₄₀H₄₄N₂O₅
• 分子量: 632.8
• InChiKey: JOZHECFHFYNZDA-HEFFKOSUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.7
• 重原子数：
  47
• 可旋转键数：
  14
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  68.3
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• USE OF TRIPHENYLBUTENE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
  申请人：AstraZeneca AB

  公开号：EP1127045A2

  公开（公告）日：2001-08-29
• US6489481B1
  申请人：——

  公开号：US6489481B1

  公开（公告）日：2002-12-03
• [EN] NEUROLOGICAL DISORDERS<br/>[FR] TROUBLES NEUROLOGIQUES
  申请人：ZENECA LTD

  公开号：WO2000025767A2

  公开（公告）日：2000-05-11

  The use of a compound of Formula (VIII) in the manufacture of a medicament for the treatment of or the prevention of neurological disorders, in a warm-blooded mammal, wherein A and B are selected from: Formula (IX) or Formula (X) such that when A is of Formula (X) then B is of Formula (IX) and when A is of Formula (IX) then B is of Formula (X). R1 is selected from hydrogen, halo, aryl, carbamoyl, N-C1-4alkylcarbamoyl or NN-di-C1-4alkylcarbamoyl; D is selected from C1-4alkylene, C1-4alkenylene or alkynylene; R2 is selected from hydrogen, C1-4alkyl or hydroxy; R3 is selected from hydrogen, hydroxy, halo, PO4, C1-4alkoxy, or a group of the formula: -E-F-G-H wherein: E is selected from: (a), (b), (c), (d), (e), or (f); F is selected from: (a), (b), or a direct bond; G is selected from C1-6alkyl, or a direct bond; H is selected from hydrogen, C1-4alkoxy, or optionally substituted aryl; heteroaryl, or carbocyclyl; R4 and R5 are independently selected from methyl, ethyl or phenyl, or together with the nitrogen atom to which they are attached form a ring selected from pyrrolidine, piperidine or morpholine; R6 is selected from hydrogen, C1-4alkyl; C1-4alkoxy, halo, or a ring fused phenyl group fused via carbons 3 and 4 on the phenyl group of Formula (X); R7 and R8 are either both hydrogen or when A is of Formula (X) may be joined either via a sulphur atom, via -CH2- or via -C2H4; R9 is selected from hydrogen or C1-4alkyl; and n is 2 or 3; or a pharmaceutically acceptable salt, prodrug or solvate thereof. Processes for their preparation of compounds of Formula (VIII) are described, as are compositions containing them and their use.